Team
Founded in 2019 by a technical team of vaccine and software developers, Baseimmune is accelerating discovery of novel and cross-protective vaccines. Our founders pioneered the use of computational approaches to design cross-protective vaccines against various infectious diseases while at the Jenner Institute University of Oxford with two candidates in clinical trials.
Leadership
Co-founder, CEO
Co-founder, CSO
Co-founder, CTO
Board of Directors
Jamie
Macfarlane
Creator Fund
Hussein
Kanji
Hoxton Ventures
Alex
Wilson
IQ Capital
Joshua
Blight
Baseimmune
Ariane
Gomes
Baseimmune
Phillip
Kemlo
Baseimmune
Advisory Board
Danny
Goovaerts
Prof. Jake
Baum
Prof. Molly Stevens
Veterinary Commercial Advisor
Scientific Advisor
Scientific Advisor
Pipeline
Our early-stage pipeline includes two human vaccines against Malaria (BSI002) and a pancoronavirus vaccine (BSI001), and a veterinary vaccine against African Swine Fever (BSI001). All candidates are currently being tested as mRNA/LNP or viral vectors.
BSI002
Universal Malaria Vaccine
BSI003
Veterinary
FEASIBILITY
EARLY-STAGE DEVELOPMENT
Universal African Swine Fever Vaccine
BSI001
Working with world-class
Funded and supported by
© 2023 Baseimmune. All rights reserved
London BioScience Innovation Centre, 2 Royal College Street, London, NW1 0NH
—
Designed and created with love by the Baseimmune Team ♥︎
baseimmune
®
